Eledon Pharmaceuticals (ELDN) Total Liabilities (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Total Liabilities data on file, last reported at $46.2 million in Q1 2026.

• Quarterly Total Liabilities fell 1.11% year-over-year to $46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.2 million (down 1.11% YoY) and the FY2025 annual result came in at $32.2 million, down 45.62% from the prior year.
• Total Liabilities advanced to $46.2 million in Q1 2026, from $32.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $129.0 million in Q2 2024 to a low of $5.1 million in Q1 2022.
• A 5-year average of $45.0 million and a median of $38.9 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 1171.57% — and 2025, when it tumbled 69.86%.
• Tracing ELDN's Total Liabilities over 5 years: stood at $8.6 million in 2022, then surged by 850.73% to $81.9 million in 2023, then retreated by 27.6% to $59.3 million in 2024, then plunged by 45.62% to $32.2 million in 2025, then jumped by 43.37% to $46.2 million in 2026.
• The last three Total Liabilities figures came in at $46.2 million (Q1 2026), $32.2 million (Q4 2025), and $38.8 million (Q3 2025), per Business Quant data.